Autologous peripheral blood stem cell (PBSC) transplantation results in rapid hematologic recovery when sufficient numbers of CD34 ؉ cells/kg are infused. Recent studies suggest that filgrastim (G-CSF) administration following transplantation leads to more rapid neutrophil recovery and lower total transplant costs. This study compares the use of G-CSF (5 g/kg/day) with sargramostim (GM-CSF) 500 g/day from day 0 until neutrophil recovery (ANC Ͼ1500/mm 3 ) in patients with breast cancer or myeloma who had PBSC mobilized with the combination of cyclophosphamide, etoposide, and G-CSF. Twenty patients (13 breast cancer and seven myeloma) received GM-CSF and 26 patients (14 breast cancer and 12 myeloma) received G-CSF. The patients were comparable for age and stage of disease, and received stem cell grafts that were not significantly different (CD34 ؉ ؋10
Peripheral blood stem cells (PBSC) have almost completely replaced bone marrow as the source of hematopoietic stem cells for autologous transplantation. [1] [2] [3] The advantages of PBSC over bone marrow include faster hematologic and probably immunologic recovery, shorter in-hospital stay, lower total transplant costs, and probably lower transplantrelated mortality. [4] [5] [6] It is unclear whether the use of hematopoietic growth factors after transplantation hastens hematologic recovery if sufficient numbers of PBSC have been infused. [7] [8] [9] [10] [11] Sheridan et al 7 saw very rapid hematologic recovery after the infusion of PBSC mobilized with G-CSF (filgrastim), even without the use of growth factors after stem cell reinfusion. An absolute neutrophil count (ANC) Ͼ500/mm 3 was reached at a median of 9 days, and platelets Ͼ50 000/mm 3 at a median of 15 days. However, Spitzer et al 8 reported a group of patients who received steady-state bone marrow plus PBSC mobilized with a combination of G-CSF and GM-CSF (sargramostim). After progenitor cell reinfusion, the patients either received no growth factor or received a combination of G-CSF (7.5 g/kg/day) and GM-CSF (2.5 g/kg/day). 8 Patients who received the combination had significantly faster hematologic recovery (ANC Ͼ500/mm 3 at medians of 10 vs 16 days).
Four recent studies compared G-CSF after PBSC transplantation with placebo. Klumpp et al 9 studied patients who received PBSC mobilized with a variety of regimens. Half the patients also received bone marrow cells infused. The patients who were treated with G-CSF 5 g/kg/day from day ϩ1 had faster neutrophil recovery than patients who did not receive growth factors. The median duration to ANC Ͼ500/mm 3 was 10.5 vs 15 days. 9 Tarella et al 10 used G-CSF 5 g/kg/day after reinfusion of PBSC mobilized with chemotherapy and G-CSF. When compared to a historical control group which did not receive G-CSF, the patients given G-CSF had faster hematologic recovery (ANC Ͼ500/mm 3 at a median of 10 vs 14 days, and platelets Ͼ20 000/mm 3 at a median of 11 vs 13 days), resulting in shorter hospitalization and lower treatment costs.
McQuaker et al 11 found the same decline in the median number of days to ANC Ͼ500/mm 3 (10 days in the G-CSF group and 14 in the placebo group) using only 50 g/m 2 of G-CSF after reinfusion of stem cells mobilized with chemotherapy and G-CSF. Again, the days of hospitalization and the total costs were also less for the G-CSF group. Linch et al 12 reported similar results when comparing lenograstim, a different formulation of G-CSF, to no growth factor after reinfusion of PBSC which had been mobilized with chemotherapy and lenograstim. The median time to ANC Ͼ500/mm 3 was 9 days in the lenograstim group vs 12.5 days in the no-growth factor group.
Legros et al 13 compared GM-CSF with placebo after the reinfusion of PBSC mobilized with chemotherapy and GM-CSF. The median number of days to ANC Ͼ500/mm 3 was 12 for the GM-CSF patients and 14 for the placebo group (P = NS). Resource utilization was similar in both groups. Bolwell et al 14 found that G-CSF led to more rapid engraftment than GM-CSF, but this conclusion might have been biased by the fact that patients who received G-CSF post-transplant had also been mobilized with G-CSF, while the patients given GM-CSF after transplant had received GM-CSF mobilized stem cells. It has been suggested that G-CSF is a more active mobilizing agent than GM-CSF. 6, 14, 15 No published reports have compared G-CSF and GM-CSF in patients who received PBSC mobilized with the same regimen. In the current study, all patients received PBSC that were obtained following mobilization with the same chemotherapy and G-CSF regimen. After reinfusion of PBSC, patients received either G-CSF (5 g/kg/day) or GM-CSF (500 g/day).
Materials and methods

Patients
Patients with metastatic (stage IV) or locally advanced (stage II or III) breast cancer were eligible for this study if they were acceptable candidates for high-dose chemotherapy with PBSC rescue. Similarly, patients with multiple myeloma who were candidates for high-dose chemotherapy were eligible. Patients were treated at two Indiana Blood and Marrow Transplantation sites within the Indianapolis metropolitan area by the same four transplant physicians on a rotational schedule. Written program-wide policies and procedures for mobilizing chemotherapy, leukapheresis, supportive care, antibiotic prophylaxis, and indications for admission and institution of intravenous antibiotics were followed. Eligibility for high-dose chemotherapy was centrally decided for any deviation from written criteria. All patients gave written informed consent for all treatment given during this study.
Mobilization therapy and stem cell collection
Patients eligible for high-dose chemotherapy underwent mobilization chemotherapy with cyclophosphamide (cytoxan; Bristol-Myers Squibb, Princeton, NJ, USA) 4000 mg/m 2 over 1-2 h on day 1, and etoposide (VP-16) 200 mg/m 2 /day over 2-3 h on days 1 and 2. On day 3 all patients started G-CSF 10 g/kg/day s.c. Leukapheresis was initiated when the peripheral blood WBC exceeded 3000/mm 3 , approximately day 12 or 13. A COBE Spectra (Lakewood, CO, USA) was used to collect 2. to 3 blood volumes per day with a flow rate of 60-120 ml/min. Venous access was achieved with a Quinton Permcath dialysis catheter (Quinton, Bothell, WA, USA). Cells were collected in ACD-A and transported to the IBMT Stem Cell Laboratory. There, aliquots were taken for quantification of CD34 and for bacterial cultures. The stem cell products were frozen in Fenwal cryopreservation bags (Fenwal, Baxter, Deerfield, IL, USA) (100 ml) with 10% DMSO using a Cryomed controlled rate freezer (New Baltimore, MD, USA). 16 The bags were stored in the liquid phase of liquid N 2 . The collection goal was 5 ϫ 10 6 CD34 ϩ cells per kg. Cryopreservation and CD34 enumeration for both sites (A and B) were performed in a single laboratory.
High-dose chemotherapy with PBSC rescue
Transplant episodes were commonly started on an outpatient basis with admission for occurrence of any of the predefined written criteria. If a non-medical caregiver was unavailable, patients were automatically treated as inpatients. The preparative regimen for patients with breast cancer was carboplatin, thiotepa and cyclophosphamide (modified STAMP-V). 17 Carboplatin was dosed at 267 mg/m 2 /day ϫ 3 and infused over 30 min, thiotepa at 167 mg/m 2 /day ϫ 3 over 2 h, and cyclophosphamide at 2000 mg/m 2 /day ϫ 3 over 2 h. Mesna was used by continuous infusion over 72 h. PBSC were infused 3 days after the last chemotherapy. For patients with myeloma, the preparative regimen consisted of melphalan 100 mg/m 2 /day ϫ 2 over 1-2 h, with PBSC reinfused 2 days after the second dose of melphalan. 18 PBSC were transported to the bedside in liquid N 2 , the aluminum containers were opened, and the Fenwal bags thawed in a 40°C sterile saline bath. The contents were infused into a central venous catheter with a syringe at the rate of 50 cc per 5-10 min. All patients received prophylactic ciprofloxacin, cephalexin, fluconazole and acyclovir to prevent infections during the period of myelo-and immunosuppression.
Hematopoietic growth factors
Successive patients with breast cancer or myeloma at each of the two sites were assigned to either GM-CSF at 500 g/day s.c. (site A) or G-CSF at 5 g/kg/day s.c. (site B). The growth factors were started 4 h after the infusion of the stem cells and repeated each day at the same time. The growth factor injections were discontinued when the ANC exceeded 1500/mm 3 for the third consecutive day.
Statistics
The two-tailed Mann-Whitney test was used to compare parameters between the two groups in situations where the data did not appear to have normal distribution. For situations with normal distribution, a two-tailed t-test was used.
The chi-square test was used to compare the diagnosis groups. A P value of Ͻ0.05 was considered to indicate a significant difference.
Results
The clinical data for the 46 patients studied are shown in Table 1 . Twenty-seven women suffered from breast cancer. Twelve of them had metastatic breast cancer (stage IV) and had previously received up to six cycles of adjuvant chemotherapy initially. At relapse, they underwent induction 1253 Table 1 Clinical data for the 46 patients studied chemotherapy for up to four cycles, followed by mobilizing treatment and high-dose chemotherapy with PBSC rescue. The remaining 15 women with breast cancer had locally advanced disease and underwent high-dose chemotherapy as part of their initial therapy after four cycles of adjuvant chemotherapy. Nineteen patients had multiple myeloma and underwent high-dose chemotherapy in first or second (partial) remission. Twenty patients were enrolled at site A, and 26 patients at site B. As shown in Table 1 , the patients were comparable for diagnosis, stage, and age. All patients were evaluable, and no patient died during the treatment phase. Table 2 shows the results of the PBSC collections for both groups. The patients assigned to GM-CSF underwent on average 2 Ϯ 0.8 (mean Ϯ s.d.) collections, and the patients assigned to G-CSF 2.3 Ϯ 1.6 collections (P = 0.97). The number of collected WBC/kg and CD34 ϩ cells/kg tended to be somewhat higher for the G-CSF group, but the difference did not reach statistical significance. Specifically, the average number of CD34 ϩ cells/kg collected was 12.5 ϫ 10 6 for the GM-CSF group and 19.8 ϫ 10 6 for the G-CSF group (P = 0.14). All patients received at least 3.8 ϫ 10 6 CD34 ϩ cells/kg, and 90% of the patients in the GM-CSF group, and 92% of the patients in the G-CSF received doses of Ͼ5.0 ϫ 10 6 CD34 ϩ /kg.
GM-CSF G-CSF P
Mobilization phase
Stem cell transplant phase
All patients engrafted promptly and reached ANC Ͼ500/mm 3 within 7-14 (median 9) days, and ANC Ͼ1000/mm 3 within 7-14 (median 10) days. Most patients also had rapid recovery of platelets, with 44 patients reaching platelet counts Ͼ50 000/mm 3 after 8-19 (median 12) days. Two breast cancer patients had slower platelet recov- Table 2 Composition of the peripheral blood stem cell grafts
GM-CSF G-CSF P (site A) (site B)
Number of collections 2.0 ± 0.8 2. ery and did not reach 50 000/mm 3 until 42 and 48 days after PBSC infusion. The rapid hematologic recovery led to a very modest use of blood products. The median number of platelet transfusions (mostly single-donor pheresis platelets) was 2 (range, 0-15), and the median number of red cell transfused units was also 2 (range, 0-8 units). The duration of fever (Ͼ38.3°C) was 0-9 days (median 1 day). Fourteen patients (30%) did not have any temperature Ͼ38.3°C during their neutropenic episode. Patients were routinely started on intravenous antibiotics if they had a temperature Ͼ38.3°C. Ten patients did not receive any intravenous antibiotics. The remaining 36 patients were treated with intravenous antibiotics for a median of 5.5 (range, 1-14) days.
GM-CSF versus G-CSF
Twenty patients received GM-CSF and 26 patients received G-CSF. As shown in Table 3 , the patients who received G-CSF reached ANC Ͼ500/mm 3 at 8.8 Ϯ 1.2 (mean Ϯ s.d.) days, and the patients on GM-CSF at 10.5 Ϯ 1.5 days (P Ͻ 0.001; Figure 1 ). ANC Ͼ1000/mm 3 was reached at 8.9 Ϯ 2.2 days (G-CSF) and 11.0 Ϯ 1.7 days (GM-CSF) (P = 0.001). Independence of platelets (Ͼ20 000/mm 3 without transfusion) was reached after 9.9 Ϯ 1.1 days in the GM-CSF group and after 11.2 Ϯ 4.7 days in the G-CSF group (P = 0.4; Figure 2 ). Mean platelets Ͼ50 000/mm 3 were reached earlier in the GM-CSF group (11.8 Ϯ 2.1 days) than in the G-CSF group (14.9 Ϯ 9.4 days), but again the difference was not significant (P = 0.37). The large standard deviation for the G-CSF group was caused by two patients with slow platelet recovery. The median day to platelets Ͼ20 000/mm 3 was 10 for both GM-CSF and G-CSF, and to platelets Ͼ50 000/mm 3 was 12 (GM-CSF) and 12.5 (G-CSF). The requirement for platelet transfusions and for red cells was not different between the two groups, with P values of 0.80 and 0.21, respectively.
Since neutrophils recovered more rapidly in the G-CSF group, the number of growth factor injections necessary to reach an ANC Ͼ1500/mm 3 for 3 consecutive days was less for this group. G-CSF patients received 10.8 Ϯ 2.1 injections, and GM-CSF patients received 12.2 Ϯ 1.5 injections (P = 0.001). No difference was found between the two groups for the number of days with fever, or for the number of days on intravenous antibiotics (Table 3 ). The percentage of patients without any fever was also similar for the two groups (37% on GM-CSF vs 50% on G-CSF).
Utilization of resources
Most of the patients started their transplant as an outpatient depending upon the availability of a non-medical caregiver, expected compliance with therapy, and payer considerations. Therefore, cost of hospitalization was not used as a parameter for resource utilization. It was decided to analyze only those costs that appeared directly related to the pancytopenic episode. Thus, the costs of growth factors, blood products, antibiotics, and extra laboratory tests (blood cultures ϫ 2, urine culture, chest X-ray) associated with fever spikes, were used as parameters to compare the resources used for the two groups. Drugs were calculated at average wholesale price, blood products at blood-center charges ϩ 10%, and nursing services at 70% of charges. The costs for the limited package described above, varied between $2080 and $21 570 for patients in the G-CSF group, and between $3620 and $12 200 for patients in the GM-CSF group. The mean Ϯ s.d. was $7473 Ϯ $4123 for the G-CSF group and $6317 Ϯ $2097 for the GM-CSF group. This difference between the two groups was not significant (P = 0.56). 
Discussion
The results of this study suggest that daily G-CSF administration after PBSC infusion leads to a shorter neutropenic episode than with GM-CSF. As shown in Table 3 and in Figure 1 , G-CSF appears to accelerate the recovery of neutrophils by about 2 days as compared to GM-CSF. Since no placebo control was included, it could not be determined whether GM-CSF accelerated neutrophil recovery at all. However, in studies comparing G-CSF with placebo under conditions fairly similar to the current study, G-CSF resulted in ANC Ͼ500/mm 3 at medians of 9-10.5 days, respectively, while in the placebo group the median was 14-16 days (9-12). In the current study nearly all GM-CSF patients had an ANC Ͼ500/mm 3 by day 12 ( Figure  1 ), suggesting that GM-CSF probably did lead to a modest shortening of the neutropenic episode. As has been reported by other investigators, the infusion of a large dose of CD34 ϩ cells/kg resulted in rapid hematologic recovery for the entire study population. [19] [20] [21] [22] In fact, in only two patients both in the G-CSF group, was the recovery of platelets delayed beyond day ϩ21. The extensive use of platelets (15 transfusions) in one of these patients was more likely attributable to a high level of allo-immunization than to slow platelet recovery.
Several factors may have contributed to the outcome of this study. First, allocation of patients to the two arms of this study was not a true randomization, but was rather decided on the basis of the site where they were treated (GM-CSF at site A, G-CSF at site B). All patients were treated by the same small group of transplant physicians using identical protocols and the same stem-cell laboratory, but it is possible that the referral pattern to these two sites may have induced a bias. The number of patients at both sites with breast cancer and myeloma was similar (Table  1) . Second, the patients in the G-CSF group received, on average, more CD34 ϩ cells/kg than the GM-CSF patients (Table 2) . In this study, a modest inverse correlation was found between the number of CD34 ϩ cells/kg infused and days to ANC Ͼ500/mm 3 (r = −0.43; P = 0.01). The slightly, but not significantly, higher dose of CD34 ϩ cells/kg in the G-CSF group might have resulted in more rapid neutrophil recovery. On the other hand, if only patients who received CD34 ϩ cell doses Ͻ10.0 ϫ 10 6 /kg are considered, eight patients remain in the GM-CSF group, and 11 patients in the G-CSF group. The doses of CD34 ϩ cells/kg were 6.1 Ϯ 1.7 ϫ 10 6 for the GM-CSF group and 6.4 Ϯ 3.2 x 10 6 for the G-CSF group (P = 0.67). The G-CSF group still had faster neutrophil recovery, with ANC Ͼ500/mm 3 after 9.5 Ϯ 0.9 days as compared to 10.7 Ϯ 1.6 days for GM-CSF (P Ͻ 0.02). Thus, the larger dose of CD34 ϩ cells/kg does not appear to have caused the differences in neutrophil recovery. Furthermore, the faster neutrophil recovery for the G-CSF group was also present if breast cancer patients and myeloma patients were analyzed separately (for breast cancer P = 0.01, and for myeloma P = 0.005; data not shown). The more rapid neutrophil recovery after G-CSF led to a smaller number of G-CSF injections (Table 3) .
No differences were observed for any other clinical parameters studied. We did not find a difference between the two groups for platelet recovery, either at the 20 000/mm 3 or the 50 000/mm 3 level. In fact, for the entire group of patients no significant correlation was found between the dose of CD34 ϩ cells/kg and days to platelets Ͼ20 000/mm 3 (r = −0.22; P Ͼ 0.1). This observation is in agreement with the results of Bensinger et al, 20 who also failed to observe such a correlation in patients infused with more than 5.0 ϫ 10 6 CD34 ϩ cells/kg. Patients given GM-CSF vs G-CSF needed similar numbers of platelets and red cell transfusions, had similar numbers of days with temperature Ͼ38.3°C, and of days on intravenous antibiotics. When a limited package of costs immediately associated with the use of growth factor and with the consequences of pancytopenia was considered, no clear differences were found in resource utilization. Actually, in spite of more days of GM-CSF, the average total costs for patients in the GM-CSF arm were slightly lower than for patients in the G-CSF arm ($6317 vs $7473), but the difference was not significant (P = 0.56). The cost of platelet transfusions had a major impact on resource utilization, since platelets constituted 30-35% of the total cost in the model. This percentage is close to the 37% of the resource package accounted for by the growth factors. The cost of hospitalization was not considered. For an inpatient transplant, if discharge is dependent upon an arbitrarily set ANC, the faster neutrophil recovery after G-CSF might well have considerable financial impact. However, the economic impact of slightly faster neutrophil engraftment would appear to be far less pronounced in an outpatient model. This study does not address the optimal dose of G-CSF (or GM-CSF) sufficient for rapid hematologic recovery, nor the optimal starting date for the growth factor following PBSC reinfusion. The doses used in this study were similar to those used in many other studies. 9, 10, 19, 21, [23] [24] [25] It may well be that far lower doses are in fact sufficient to achieve the same rapid recovery. Indeed, McQuaker et al 11 reported results similar to the current study using only 50 g/m 2 G-CSF, and To et al 1 recommended a standard dose of 300 g/day. Furthermore, beyond dose considerations, growth factors may not need to be started on the day of PBSC reinfusion, as delays of up to 6 days have been reported not to adversely affect engraftment. 26, 27 Future assessments of cost effectiveness of growth factors after autologous PBSC transplantation need to address the issues of optimal dose and timing.
